Mosapride significantly enhances gastrointestinal recovery following elective colorectal cancer surgery. In a randomized controlled trial involving 44 patients, those receiving mosapride experienced their first bowel movement in an average of 26 hours compared to 50 hours for the control group (p=0.004). Similarly, the time to passage of flatus was reduced from 70 hours to 40 hours (p=0.003). The treatment also resulted in a shorter hospital stay without serious adverse effects, illustrating its potential benefits.
Journal Article by Thampongsa T, Saengsawang B (…) Singhathas P et 7 al. in Ann Coloproctol